Get the Stockscreener App
112.21
0.02%
0.02
After Hours:
112.21
Overview
News
Price History
Option Chain
Financials
Discussions
Forecast
Stock Split
Dividend History
Abbott Laboratories stock is traded at $112.21, with a volume of 6.99M.
It is up +0.02% in the last 24 hours and down -7.37% over the past month.
Abbott manufactures and markets cardiovascular and diabetes devices, adult and pediatric nutritional products, diagnostic equipment and testing kits, and branded generic drugs. Products include pacemakers, implantable cardioverter defibrillators, neuromodulation devices, coronary stents, catheters, infant formula, nutritional liquids for adults, continuous glucose monitors, and immunoassays and point-of-care diagnostic equipment. Abbott derives roughly 60% of sales outside the United States.
See More
Previous Close:
$112.19
Open:
$112.19
24h Volume:
6.99M
Relative Volume:
0.79
Market Cap:
$195.12B
Revenue:
$44.33B
Net Income/Loss:
$6.48B
P/E Ratio:
30.30
EPS:
3.7033
Net Cash Flow:
$6.92B
1W Performance:
-0.42%
1M Performance:
-7.37%
6M Performance:
-15.27%
1Y Performance:
-15.74%
1-Day Range:
$111.18
$112.64
1-Week Range:
$111.18
$113.59
52-Week Range:
$105.27
$140.84
Abbott Laboratories Stock (ABT) Company Profile
Name
Abbott Laboratories
Sector
Industry
Phone
(224) 667-6100
Address
100 ABBOTT PARK ROAD, ABBOTT PARK, IL
Compare ABT vs SYK, MDT, BSX, EW
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
ABT
Abbott Laboratories
|
112.21 | 195.08B | 44.33B | 6.48B | 6.92B | 3.7033 |
|
SYK
Stryker Corp
|
380.23 | 142.61B | 25.12B | 3.25B | 4.28B | 8.3984 |
|
MDT
Medtronic Plc
|
96.86 | 125.10B | 35.48B | 4.64B | 5.41B | 3.5856 |
|
BSX
Boston Scientific Corp
|
74.58 | 112.29B | 20.08B | 2.89B | 3.66B | 1.9391 |
|
EW
Edwards Lifesciences Corp
|
79.78 | 45.80B | 6.07B | 1.06B | 799.60M | 1.8527 |
Abbott Laboratories Stock (ABT) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-10-25 | Initiated | The Benchmark Company | Buy |
| Jul-18-25 | Upgrade | Jefferies | Hold → Buy |
| Jun-16-25 | Initiated | Leerink Partners | Market Perform |
| Oct-08-24 | Initiated | Oppenheimer | Outperform |
| Sep-19-24 | Initiated | Piper Sandler | Overweight |
| Jul-30-24 | Downgrade | Edward Jones | Buy → Hold |
| May-30-24 | Initiated | Goldman | Buy |
| Jul-21-23 | Upgrade | Wolfe Research | Underperform → Peer Perform |
| May-30-23 | Downgrade | Morgan Stanley | Overweight → Equal-Weight |
| Apr-20-23 | Reiterated | Barclays | Overweight |
| Apr-20-23 | Reiterated | Bernstein | Outperform |
| Apr-20-23 | Reiterated | JP Morgan | Overweight |
| Apr-20-23 | Reiterated | Raymond James | Outperform |
| Apr-20-23 | Reiterated | UBS | Buy |
| Apr-20-23 | Reiterated | Wolfe Research | Underperform |
| Mar-29-23 | Initiated | UBS | Buy |
| Oct-26-22 | Initiated | Mizuho | Neutral |
| Oct-18-22 | Initiated | Barclays | Overweight |
| Oct-12-22 | Initiated | Jefferies | Hold |
| Jul-06-22 | Initiated | Wolfe Research | Underperform |
| Mar-02-22 | Resumed | BofA Securities | Buy |
| Jan-27-22 | Reiterated | Credit Suisse | Outperform |
| Jan-27-22 | Reiterated | Morgan Stanley | Overweight |
| Jan-27-22 | Reiterated | Raymond James | Outperform |
| Jan-27-22 | Reiterated | UBS | Buy |
| Dec-10-21 | Initiated | RBC Capital Mkts | Outperform |
| Oct-27-21 | Upgrade | Atlantic Equities | Neutral → Overweight |
| Oct-14-21 | Initiated | Redburn | Neutral |
| May-25-21 | Initiated | Barclays | Overweight |
| Apr-15-21 | Initiated | Atlantic Equities | Neutral |
| Jan-28-21 | Upgrade | BTIG Research | Neutral → Buy |
| Sep-11-20 | Initiated | Wolfe Research | Outperform |
| Jun-01-20 | Downgrade | Goldman | Neutral → Sell |
| Mar-05-20 | Initiated | Citigroup | Buy |
| Feb-13-20 | Initiated | Goldman | Neutral |
| Feb-06-20 | Resumed | BTIG Research | Neutral |
| Jan-02-20 | Downgrade | Guggenheim | Buy → Neutral |
| Jun-13-19 | Reiterated | BofA/Merrill | Buy |
| Feb-07-19 | Reiterated | BofA/Merrill | Buy |
| Jan-02-19 | Downgrade | Citigroup | Neutral → Sell |
| Nov-30-18 | Upgrade | Goldman | Neutral → Buy |
| Oct-16-18 | Initiated | Barclays | Overweight |
| Jun-27-18 | Initiated | Bernstein | Outperform |
| Jan-30-18 | Reiterated | Citigroup | Neutral |
| Jan-25-18 | Reiterated | Stifel | Buy |
| Jan-25-18 | Upgrade | William Blair | Mkt Perform → Outperform |
| Jan-03-18 | Initiated | Evercore ISI | Outperform |
| Jan-02-18 | Upgrade | JP Morgan | Neutral → Overweight |
| Jan-02-18 | Upgrade | Morgan Stanley | Equal-Weight → Overweight |
| Oct-19-17 | Reiterated | RBC Capital Mkts | Outperform |
| Oct-19-17 | Reiterated | Stifel | Buy |
View All
Abbott Laboratories Stock (ABT) Latest News
Abbott Laboratories $ABT Shares Sold by Tredje AP fonden - MarketBeat
Siligmueller & Norvid Wealth Advisors LLC Purchases Shares of 11,538 Abbott Laboratories $ABT - MarketBeat
Raiffeisen Bank International AG Purchases 33,095 Shares of Abbott Laboratories $ABT - MarketBeat
China Universal Asset Management Co. Ltd. Sells 15,607 Shares of Abbott Laboratories $ABT - MarketBeat
Rep. Thomas H. Kean, Jr. Purchases Shares of Abbott Laboratories (NYSE:ABT) - MarketBeat
Pay Less, Gain More: STE, RMD Top Abbott Laboratories Stock - Trefis
Decoding Abbott Laboratories (ABT): A Strategic SWOT Insight - GuruFocus
Abbott Laboratories (ABT) Announces Positive Results for Amulet 360 Left Atrial Appendage (LAA) Occlude - Finviz
Abbott Laboratories (ABT) Announces Board of Directors Restructu - GuruFocus
Exact Sciences shareholders approve merger with Abbott Laboratories - Investing.com
Exact Sciences stockholders approve acquisition by Abbott - marketscreener.com
Exact Sciences Shareholders Approve Merger with Abbott Laboratories - TipRanks
Abbott Laboratories Streamlines Governance With Smaller Board - TipRanks
Abbott (ABT) to Acquire Exact Sciences Following Stockholder App - GuruFocus
Exact Sciences Shareholders Approve Acquisition by Abbott Laboratories - marketscreener.com
ABBOTT LABORATORIES SEC 10-K Report - TradingView
Exact Sciences Stockholders Approve Acquisition by Abbott - Stock Titan
Thomas Kean Jr makes strategic moves in Abbott Laboratories and General Motors - Investing.com
Abbott Laboratories (ABT) Maintains Quarterly Dividend - GuruFocus
Abbott declares 63-cent quarterly dividend, 409th consecutive - Investing.com
Abbott Laboratories Declares Quarterly Cash Dividend, Payable on May 15, 2026 - marketscreener.com
Abbott Keeps Quarterly Dividend at $0.63 a Share, Payable May 15 to Holders of Record as of April 15 - marketscreener.com
Abbott declares quarterly dividend of 63 cents per share - marketscreener.com
Abbott declares 409th consecutive quarterly dividend - PR Newswire
Woodley Farra Manion Portfolio Management Inc. Has $61.18 Million Stock Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock Is Down 16% From Its 52-Week High. Here’s Where the Stock Could Go in 2026 - TIKR.com
BSX vs. ABT: Which MedTech Stock is the Better Investment Now? - TradingView
NewEdge Wealth LLC Has $6.20 Million Stake in Abbott Laboratories $ABT - MarketBeat
Weight Management Supplements Market Report 2026: A $15+ - GlobeNewswire
Abbott unit defends European protection for heart valve ‘cuff’ design - Life Sciences Intellectual Property Review
Pharma Giants Amgen & Abbott Labs Commit to Transition Away from Horseshoe Crab Blood in Biomedical Testing Following Shareholder Engagement - As You Sow
Hemenway Trust Co LLC Has $45.81 Million Holdings in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories: The Quiet Healthcare Giant You’re Sleeping On - AD HOC NEWS
ABT.SW Abbott Laboratories CHF100.00 pre-market 19 Feb 2026: Oversold bounce - Meyka
BTIG Research Has Lowered Expectations for Abbott Laboratories (NYSE:ABT) Stock Price - MarketBeat
Abbott Laboratories (ABT) Is a Trending Stock: Facts to Know Before Betting on It - Yahoo Finance
First National Bank of Omaha Makes New $19.85 Million Investment in Abbott Laboratories $ABT - MarketBeat
Axxcess Wealth Management LLC Has $18.75 Million Stock Position in Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Bought by Ingalls & Snyder LLC - MarketBeat
3 Large-Cap Stocks with Solid Fundamentals - The Globe and Mail
How The Abbott Offer Is Rewriting The Story For Exact Sciences (EXAS) - Yahoo Finance
NEOS Investment Management LLC Acquires 72,502 Shares of Abbott Laboratories $ABT - MarketBeat
Merit Financial Group LLC Grows Holdings in Abbott Laboratories $ABT - MarketBeat
Skandinaviska Enskilda Banken AB publ Buys 190,255 Shares of Abbott Laboratories $ABT - MarketBeat
A Look At Abbott Laboratories (ABT) Valuation As Libre 3 Lawsuit Raises Product Safety Concerns - simplywall.st
Abbott class action claims glucose sensors sold with defect - Class Action Lawsuits
Southeast Asset Advisors LLC Acquires 9,600 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories $ABT Shares Purchased by Vanguard Group Inc. - MarketBeat
Pallas Capital Advisors LLC Reduces Stock Position in Abbott Laboratories $ABT - MarketBeat
Shell Asset Management Co. Trims Stock Position in Abbott Laboratories $ABT - MarketBeat
Fifth Third Bancorp Sells 10,616 Shares of Abbott Laboratories $ABT - MarketBeat
Abbott Laboratories Stock (ABT) Financials Data
Revenue
Net Income
Cash Flow
EPS
Abbott Laboratories Stock (ABT) Insider Trading
| Insider Trading | Relationship | Date | Transaction | Cost | #Shares | Value ($) | #Shares Total |
|---|---|---|---|---|---|---|---|
| Ford Robert B | CHAIRMAN AND CEO |
Jan 23 '26 |
Buy |
107.13 |
18,800 |
2,013,967 |
216,203 |
| Shroff Eric | Senior Vice President |
Nov 25 '25 |
Sale |
128.02 |
1,586 |
203,043 |
30,384 |
2.03%
0.74%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):